Improving Targeting with Antibody & AAV-Mediated Delivery of Nucleic Acid Drugs for Muscular Disorders to Reduce Off Target Effects & Enhance Efficacy

• Utilizing AAV delivery systems to improve targeting of therapeutic payload to relevant tissues with efficacy
• Evaluating antibody-mediated delivery to overcome biodistribution challenges and reduce toxicity
• Enhancing targeting to improve therapeutic index of nucleic acid drugs and support safer and more efficacious clinical outcomes

Speakers:

Mathias Schmidt

President & Chief Executive Officer

JCR Pharmaceuticals